Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

AbbVie Deutschland GmbH & Co. KG

AbbVie Deutschland GmbH clinical programs — 45 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

AbbVie Deutschland GmbH projects

45 ClinicalTrials.gov programs sponsored by AbbVie Deutschland GmbH.

AbbVie Deutschland GmbH has 45 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

45 programs

Clinical programs

  1. 192024-092

    AbbVie Deutschland GmbH & Co. KG

    Ocular hypertension, Open-angle glaucoma

    phase 3 small molecule active

    1 trial

  2. Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)

    phase 3 small molecule active

    1 trial

  3. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  4. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  5. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 3 small molecule active

    1 trial

  6. Bimatoprost SR

    AbbVie Deutschland GmbH & Co. KG

    Open-angle Glaucoma, Ocular Hypertension

    phase 3 small molecule active

    1 trial

  7. Ibrutinib hard capsule for oral use, Ibrutinib

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  8. Lutikizumab, Placebo of Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  9. M10-870

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  10. M13-494

    AbbVie Deutschland GmbH & Co. KG

    R/R Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. M14-533

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  12. M14-671

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  13. M14-682

    AbbVie Deutschland GmbH & Co. KG

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  14. M15-656

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  15. M15-954

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  16. M15-998

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  17. M16-000

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  18. M16-011

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  19. M16-043

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  20. M16-066

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  21. M16-194

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  22. M16-852

    AbbVie Deutschland GmbH & Co. KG

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  23. M17-380

    AbbVie Deutschland GmbH & Co. KG

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  24. M19-063

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  25. M19-708

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial

  26. M19-751

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  27. M20-621

    AbbVie Deutschland GmbH & Co. KG

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  28. M20-638

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  29. M22-003

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  30. M22-128

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  31. M22-574

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  32. M23-716

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial

  33. M23-721

    AbbVie Deutschland GmbH & Co. KG

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  34. M23-732

    AbbVie Deutschland GmbH & Co. KG

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  35. M24-052

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  36. M24-064

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  37. M24-287

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  38. M25-287

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  39. M25-540

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  40. M25-586

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  41. M25-713

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  42. Placebo for risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  43. RGX-314-3101/M23-409

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 3 small molecule active

    1 trial

  44. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  45. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AbbVie Deutschland GmbH have?

45 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.